LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing...
Phoenix Molecular Designs Infographic Introduction to PhoenixMD PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b...
AUSTIN, Texas, Feb. 20, 2025 /PRNewswire/ -- MedCana (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade...
SCbio unveils new campaign and industry pillars igniting growth in South Carolina's thriving life sciences ecosystem CHARLESTON, S.C., Feb. 20,...
DistillerSR Customers Can Now Search for and Purchase Content Directly from CCC's Proprietary Bibliographic Database of More Than 165 million...
PARIS, Feb. 20, 2025 /PRNewswire/ -- Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million...
Enspyre is a next generation sequencing (NGS) preparation technology enabling higher sensitivity variant calling from a fraction of the data...
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance...
EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage...
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain...
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax...
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate...
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic...
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company...
AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from...
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb....
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today...
BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...